The Advances in Targeted Therapies series is a collection of online publications that focuses on therapeutic agents interfering with cancer cell proliferation and spread by inhibiting signaling pathways, inducing apoptosis, or stimulating the immune system. This activity will focus on non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer, and will include expert interviews accompanied by a series of clinical vignettes that enable participants to apply the information presented in the interviews.

This activity will contain a series of 3 modules: Lung Cancer, Breast Cancer, and Colorectal Cancer.

Lung Cancer Faculty

Suresh Ramalingam, MD
Suresh Ramalingam, MD
Professor of Hematology & Medical Oncology
Director, Translational Thoracic Malignancies Program
Winship Cancer Institute of Emory University
Atlanta, GA

Lecia Sequist, MD, MPH
Lecia Sequist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, MA

Breast Cancer Faculty

Kimberly Blackwell, MD
Kimberly Blackwell, MD
Professor of Medicine
Assistant Professor in Radiation Oncology
Duke University School of Medicine
Director, Breast Cancer Program
Duke Cancer Institute
Durham, NC

Sunil Verma, MD, MSEd, FRCPC
Sunil Verma, MD, MSEd, FRCPC
Associate Professor
University of Toronto
Chair, Breast Medical Oncology
Sunnybrook Odette Cancer Centre
Toronto, Ontario, Canada

Colorectal Cancer Faculty

Axel Grothey, MD
Axel Grothey, MD
Professor of Oncology and Consultant
Division of Medical Oncology
Department of Oncology, Mayo Clinic
Rochester, MN

John L. Marshall, MD
John L. Marshall, MD
Director, The Ruesch Center for the Cure of GI Cancer
Chief, Hematology/Oncology
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, DC

Accredited by

Physicians’ Education Resource®, LLC
Physicians’ Education Resource®, LLC


Click here for additional educational resources for this activity.

Activity Details

Release Date: May 2, 2014
Expiration Date: May 2, 2015
Credit Types: CME
Credit Amount: 3 AMA PRA Category 1 Credit™
Estimated Time for Complete Activity: 3 hours
Fee for Activity: Free of Charge

Learning Objectives

At the conclusion of this activity, participants should be better prepared to:

Module 1:

  • Evaluate emerging clinical data regarding novel targeted agents for the treatment of lung cancer
  • Assess how emerging data on the molecular classification of NSCLC can be used to individualize treatment plans for patients with NSCLC
  • Summarize guidelines from CAP, ASCO, and NCCN regarding mutational analysis for patients with advanced NSCLC
  • Identify appropriate clinical trials examining novel targeted agents that are designed to benefit patients with lung cancer

Module 2:

  • Assess the clinical data and treatment guidelines concerning the use of existing targeted agents for the treatment of breast cancer
  • Evaluate emerging clinical data regarding novel and existing targeted agents for the treatment of breast cancer
  • Identify appropriate clinical trials examining novel targeted agents that are designed to benefit patients with breast cancer

Module 3:

  • Summarize the predictive implications of KRAS testing for patients being treated for metastatic colorectal cancer
  • Assess the clinical data and treatment guidelines concerning the use of existing targeted agents for the treatment of colorectal cancer
  • Evaluate emerging clinical data regarding novel and existing targeted agents for the treatment of colorectal cancer
  • Identify clinical trials with novel targeted agents that are designed to benefit patients with colorectal cancer

Target Audience

This educational activity is directed toward community-based medical oncologists, as well as fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals.

Topics for Discussion

Module 1:

  • New Options for EGFR-Mutated Non-Small-Cell Lung Cancer
  • Overcoming Resistance to EGFR TKIs: Focus on the T790M Resistance Mutation
  • Guidelines for Molecular Testing in Lung Cancer

Module 2:

  • Ado-Trastuzumab Emtansine for Relapsed HER2+ Metastatic Breast Cancer
  • Neoadjuvant Therapy with Dual HER2 Blockade for HER2+ Breast Cancer
  • Adjuvant Trastuzumab and the Risk of Cardiotoxicity in Older Patients with HER2+ Breast Cancer

Module 3:

  • Impact of Mutation Status of EGFR Pathway Genes on the Efficacy of Cetuximab or Bevacizumab Added to FOLFIRI as First-Line Therapy for Metastatic Colorectal Cancer: FIRE-3
  • Phase III Trial of Bevacizumab Beyond First Progression for Patients With Metastatic Colorectal Cancer
  • Maintenance Therapy With Bevacizumab Plus Capecitabine After First-Line Treatment With Bevacizumab and Chemotherapy for Metastatic Colorectal Cancer: CAIRO3
  • Triplet Versus Doublet Chemotherapy in Metastatic Colorectal Cancer: FOLFOXIRI or FOLFIRI in Combination With Bevacizumab in the TRIBE Trial

Requirements for Successful Completion

In order to receive a CME certificate, participants must listen to the interviews, complete the post-test, and complete the evaluation and request for credit. Participants may immediately download a CME certificate upon completion of these steps.



Conflict of Interest Policy / Disclosure Statement

The following individuals have relevant financial relationships with commercial interests to disclose:

Suresh Ramalingam, MD – Consultant/Advisory Board: AVEO Pharmaceuticals, Ariad Pharmaceuticals, Inc., Amgen Inc., Genentech Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC, Gilead Sciences, Novartis Pharmaceuticals Corporation

Lecia Sequist, MD, MPH – Consultant: Clovis Oncology, Boehringer Ingelheim Pharmaceuticals, Merrimack Pharmaceuticals, Inc., a2  Pharmaceutical, GlaxoSmithKline

Kimberly Blackwell, MD – Grant/Research Support:  Roche/Genentech Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc.; Consultant: Novartis Pharmaceuticals Corporation, Sandoz Inc., Roche; Speaker’s Bureau: Genomic Health Inc.

Sunil Verma, MD, MSEd, FRCPC – Grant/Research Support: sanofi-aventis, Roche; Consultant: Novartis Pharmaceuticals Corporation, Eli Lilly and Company, Amgen Inc., Roche, Astra Zeneca, Eisai Inc.

Axel Grothey, MD – Grant/Research Support: Genentech Inc, Eisai, sanofi-aventis, Eli Lilly and Company

John L. Marshall, MD – Grant/Research Support: Genentech Inc, Amgen, Bayer

The following individuals have no relevant financial relationships with commercial interests to disclose: The Physicians’ Education Resource®, LLC, Planning Staff – Ann C. Lichti, CCMEP, Megan O'Connell, Dru Dace, PhD, David Lee, PhD, and Francie Jallad

Accreditation Statement for Physicians

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity is supported by educational grants from Boehringer Ingelheim and Genentech.

Disclaimer Statement

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or the companies that provided commercial support for this CME activity.

Disclosure of Unlabeled Use

This CME activity may contain discussions about off-label/unapproved uses of drugs. For additional information about approved uses, including approved indications, contraindications, and warnings, participants are advised to consult prescribing information for all products discussed or consult the Physicians’ Desk Reference. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

Contact Information for Questions About the Activity

Physicians’ Education Resource®, LLC
666 Plainsboro Road, Suite 356
Plainsboro, NJ 08536
Phone: (888) 949-0045

Hardware / Software Requirements

OpenCME recommends using the latest versions of these supported browsers: Google Chrome, Mozilla Firefox, Safari; and Microsoft Internet Explorer versions 8, 9, or 10. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Download From the ITunes App Store now!

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.